ESPU Congress 2018 - Abstract Book

227 11–14 APRIL, 2018, HELSINKI, FINLAND Current study Defoor 2006 P value (Chi-squared test) Number of patients (Male:Female) 17 (9M: 8F) 80 (38M: 42F) Median age (years) 4.2 (0.7-10.7) 10 (0.3-36) Median duration (days) 51 (7-227) 90 Indwelling or SP catheter 6 (35 %) 11 (14 %) Elevated gentamicin levels > 0.4 mg/dL 0 % 0 % Breakthrough UTI 4 (24 %) 21 (26 %) 0.82 Gentamicin resistance 1 (6 %) 5 (6 %) 0.95 CONCLUSIONS There was no difference in the safety or efficacy of intra-vesical gentamicin therapy between the current study and published literature (Defoor 2006). Intra-vesical gentamicin therapy is a safe feasible option in children with recurrent urinary tract infections and complex urological conditions.